Ceftobiprole: Difference between revisions

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 18:16, 5 February 2026

Background

Mechanism of Action

Binds to and inhibits PBP-2a on MRSA
Binds to and inhibits PBP-2x on penicillin-resistant Streptococcus pneumoniae

Spectrum of Activity

Active against MRSA, ampicillin-susceptible Enterococcus, and penicillin-resistant Streptococcus pneumoniae, as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins
Not active against Pseudomonas, ESBL-producers, or AmpC-producers

Pharmacokinetics and Pharmacodynamics

Crosses into CSF adequately

Dosing

Usual dose (CAP, SSTI): 500 mg IV q8h over 2 hours
Staphylococcus aureus bacteremia: 500 mg IV q6h for 8 days followed by q8h

Renal Dosing

CrCl	Usual Dose	High Dose (MRSA)
≥50	500 mg q8h	500 mg q6h for 8 days then q8h
30 to <50	500 mg q12h	500 mg q8h for 8 days then q12h
15 to <30	250 mg q12h	250 mg q8h for 8 days then q12h
<15	250 q24h
IHD	250 q24h (after dialysis when given on dialysis days)

Safety

Adverse Drug Reactions

Nausea, diarrhea, neutropenia (4%), dysgeusia

@@ Line 1: / Line 1: @@
-== Background ==
+==Background==
-=== Mechanism of Action ===
+===Mechanism of Action===
-* Binds to and inhibits PBP-2a on MRSA
+*Binds to and inhibits PBP-2a on MRSA
-* Binds to and inhibits PBP-2x on penicillin-resistant [[Streptococcus pneumoniae]]
+*Binds to and inhibits PBP-2x on penicillin-resistant [[Streptococcus pneumoniae]]
-=== Spectrum of Activity ===
+===Spectrum of Activity===
-* Active against [[MRSA]], ampicillin-susceptible [[Enterococcus]], and penicillin-resistant [[Streptococcus pneumoniae]], as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins
+*Active against [[MRSA]], ampicillin-susceptible [[Enterococcus]], and penicillin-resistant [[Streptococcus pneumoniae]], as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins
-* Not active against [[Pseudomonas]], ESBL-producers, or AmpC-producers
+*Not active against [[Pseudomonas]], ESBL-producers, or AmpC-producers
+=== Pharmacokinetics and Pharmacodynamics ===
-== Dosing ==
+* Crosses into CSF adequately
-* Ceftobiprole 500 mg IV q8h over 2 hours
-== Safety ==
+==Dosing==
+*Usual dose (CAP, SSTI): 500 mg IV q8h over 2 hours
-=== Adverse Drug Reactions ===
+*[[Staphylococcus aureus bacteremia]]: 500 mg IV q6h for 8 days followed by q8h
+=== Renal Dosing ===
-* Nausea, diarrhea, neutropenia (4%), dysgeusia
+{| class="wikitable"
+!CrCl
+!Usual Dose
+!High Dose (MRSA)
+|-
+|≥50
+|500 mg q8h
+|500 mg q6h for 8 days then q8h
+|-
+|30 to <50
+|500 mg q12h
+|500 mg q8h for 8 days then q12h
+|-
+|15 to <30
+|250 mg q12h
+|250 mg q8h for 8 days then q12h
+|-
+|<15
+| colspan="2" |250 q24h
+|-
+|IHD
+| colspan="2" |250 q24h (after dialysis when given on dialysis days)
+|}
+==Safety==
+===Adverse Drug Reactions===
+*Nausea, diarrhea, neutropenia (4%), dysgeusia
 [[Category:Cephalosporins]]